{"product_id":"hgh-fragment-176-191","title":"HGH Fragment 176-191","description":"\u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background \u003c\/div\u003e \u003cp class=\"prod-para\"\u003e HGH Fragment 176-191 is a C-terminal 16-amino acid fragment of human Growth Hormone (residues 176-191) that binds beta3-adrenergic receptors to stimulate lipolysis and inhibit lipogenesis independently of the GH receptor. Unlike full-length growth hormone, this fragment does not affect IGF-1 levels or insulin sensitivity, making it specifically valuable for adipose tissue metabolism research without systemic GH effects. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e This synthetic peptide fragment represents the lipolytic domain of human growth hormone, retaining the fat-metabolizing properties while eliminating the growth-promoting and glucose-modulating effects of the full hormone. The fragment functions through beta3-adrenergic receptor activation, triggering intracellular signaling cascades that promote the breakdown of stored triglycerides into free fatty acids while simultaneously inhibiting new fat synthesis. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e In research applications, HGH Fragment 176-191 demonstrates selective action on adipose tissue, particularly targeting visceral and subcutaneous fat depots. The mechanism involves enhanced lipolytic enzyme activity and reduced lipogenic enzyme expression, creating a net shift toward fat mobilization and away from fat storage. This makes it a valuable research tool for studying adipocyte metabolism, lipid partitioning, and body composition changes independent of growth hormone's anabolic effects. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e The fragment's independence from GH receptor signaling means it does not elevate IGF-1, affect glucose metabolism, or produce the growth-promoting effects associated with full-length GH. This selectivity profile allows researchers to isolate and study lipolytic mechanisms without confounding variables from other GH-mediated pathways. \u003c\/p\u003e \u003c\/div\u003e \u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data \u003c\/div\u003e \u003cdiv class=\"table-scroll\"\u003e \u003ctable class=\"prod-table\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth\u003eCompound\u003c\/th\u003e \u003cth\u003eMW \/ Formula\u003c\/th\u003e \u003cth\u003eCAS No.\u003c\/th\u003e \u003cth\u003eSequence \/ Structure\u003c\/th\u003e \u003cth\u003eReceptor \/ Target\u003c\/th\u003e \u003c\/tr\u003e \u003c\/thead\u003e \u003ctbody\u003e \u003ctr class=\"row-alt\"\u003e \u003ctd class=\"td-bold\"\u003eHGH Fragment 176-191\u003c\/td\u003e \u003ctd\u003e~1817 g\/mol\u003c\/td\u003e \u003ctd\u003e135261-71-1\u003c\/td\u003e \u003ctd\u003e16-AA C-terminal GH fragment (residues 176-191)\u003c\/td\u003e \u003ctd\u003eBeta3-adrenergic receptor agonist; lipolysis stimulator\u003c\/td\u003e \u003c\/tr\u003e \u003c\/tbody\u003e \u003c\/table\u003e \u003c\/div\u003e \u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856830632183,"sku":null,"price":55.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856830664951,"sku":null,"price":149.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856830697719,"sku":null,"price":220.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Metabolic_HGH-Fragment-176-191.jpg?v=1781180236","url":"https:\/\/generalpeptide.com\/products\/hgh-fragment-176-191","provider":"General Peptide","version":"1.0","type":"link"}